^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Loqtorzi (toripalimab-tpzi)

    i
    Other names: JS001, JS-001, JS 001, TAB-001, TAB001, terepril monoclonal antibody, treipril monoclonal antibody, TAB 001
    Company:
    Apotex, Coherus Oncology, Dr. Reddy’s, Excellmab, Hikma, LEO Pharma, Shanghai Junshi Biosci
    Drug class:
    PD1 inhibitor
    Related drugs:
    1d
    HCB101-201: Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=500, Active, not recruiting, FBD Biologics Limited | Recruiting --> Active, not recruiting | N=150 --> 500
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • carboplatin • 5-fluorouracil • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Loqtorzi (toripalimab-tpzi) • capecitabine • albumin-bound paclitaxel • Cyramza (ramucirumab) • oxaliplatin • etoposide IV • irinotecan • leucovorin calcium • HCB101
    1d
    Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy (clinicaltrials.gov)
    P2, N=170, Terminated, Sun Yat-sen University | Recruiting --> Terminated; Since the interim results of the ADRIATIC trial presented at the ASCO Annual Meeting in June 2024, the design of the control group is no longer consistent with current clinical practice.
    Trial termination
    |
    Loqtorzi (toripalimab-tpzi)
    2d
    A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=392, Active, not recruiting, LaNova Medicines Limited | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Loqtorzi (toripalimab-tpzi) • cafelkibart (LM-108)
    3d
    Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) (clinicaltrials.gov)
    P2, N=111, Recruiting, First Affiliated Hospital of Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HR positive
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Herceptin (trastuzumab) • paclitaxel • Loqtorzi (toripalimab-tpzi) • cyclophosphamide • epirubicin • trastuzumab rezetecan (SHR-A1811)
    4d
    Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Sun Yat-sen University
    New P2 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • epirubicin
    5d
    TD-NEOE3V3: Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=390, Not yet recruiting, Tang-Du Hospital | Initiation date: May 2025 --> Feb 2026
    Trial initiation date
    |
    cisplatin • docetaxel • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    5d
    FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    5d
    A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=450, Active, not recruiting, TJ Biopharma Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • Loqtorzi (toripalimab-tpzi) • uliledlimab (TJD5)
    6d
    A single-arm, single-center, prospective clinical study of trastuzumab emtansine combined with GEMOX regimen as first-line treatment for advanced biliary system tumors (ChiCTR2600117154)
    P=N/A, N=20, Completed, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New trial
    |
    Kadcyla (ado-trastuzumab emtansine) • Loqtorzi (toripalimab-tpzi)
    6d
    A Single-Arm Prospective Clinical Study on the Efficacy of Neoadjuvant Therapy with Toripalimab Combined with TP Regimen for Locally Advanced Head and Neck Tumors (ChiCTR2600117056)
    P=N/A, N=30, Not yet recruiting, The First People's Hospital of Yunnan Province; The First People's Hospital of Yunnan Province
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    6d
    Real-world Study of Toripalimab in the Application of Advanced Hepatocellular Carcinoma (ChiCTR2600116531)
    P=N/A, N=840, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New trial
    |
    Loqtorzi (toripalimab-tpzi)